Undoubtedly, point-of-care testing and molecular diagnostics have the potential to grow significantly in the upcoming years, especially after the stimulus from the recent coronavirus pandemic. They are both becoming popular options for clinical, laboratory, and at-home use for detecting different types of diseases, infections, proteins, antigens, and other targets. According to the PR Newswire (2022) press release through Bloomberg, Grand View Research, Inc. published a market analysis stating that the POCT market would be worth USD 68.59 billion by 2030. This is an increase at a CAGR of 6.8% since 2022. The research also indicated that Asia Pacific is expected to grow significantly because of higher prevalence in cancer, diabetes, cardiovascular diseases, and other infectious diseases.